Top Markets
#1 ONFA ONFA +225.03%
#2 Resolv wstUSR Resolv wstUSR +198.11%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 NKN NKN +36.62%
#6 DeAgentAI DeAgentAI +32.88%
#7 StakeStone StakeStone +27.06%
#8 BLOCKv BLOCKv +26.09%
#9 KONET KONET +22.11%
#10 OpenVPP OpenVPP +21.99%
Coin of the day
ONFA ONFA
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Kedudukan dalam Saham #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Harga Saham
$0.5275
Modal Pasaran
$1.25M
Perubahan (1 hari)
-3.56%
Perubahan (1 tahun)
-83.77%
Negara
US
Perdagangan Ensysce Biosciences, Inc. (ENSC)

Kategori

Healthcare
Margin Operasi untuk Ensysce Biosciences, Inc. (ENSC)
Margin Operasi pada March 2026 TTM: -245.89%
Menurut laporan kewangan dan harga saham terkini Ensysce Biosciences, Inc., margin operasi semasa (TTM) ialah -245.89%. Pada akhir 2023, margin operasi syarikat ialah -480.41%.
Sejarah Margin Operasi untuk Ensysce Biosciences, Inc. dari 2017 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Ubah
2026 (TTM) -245.89% 90.36%
2024 -129.17% -73.11%
2023 -480.41% -49.96%
2022 -960.05% 70.61%
2021 -562.73% 1,271.51%
2020 -41.03% -78.26%
2019 -188.72% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
Margin Operasi untuk syarikat serupa atau pesaing
Syarikat Margin Operasi Perbezaan Margin Operasi Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.17%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.14%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.10%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.10%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.10%
AU
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.